Repeated treatment with selective serotonin reuptake inhibitors but not anxiolytics prevents the stress-induced deficit of fighting behavior

Polish Journal of Pharmacology

Volumn 54, Issue 4, 2002, Pages 373-380

  Ossowska, Grazyna ^a   Zebrowska Łupina, Iwona ^a   Danilczuk, Zofia ^a   Klenk Majewska, Bozena ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Buspirone; Chronic unpredictable stress (CUS); Electric footshock induced fighting behavior; Fluoxetine; Fluvoxamine; Lorazepam; Oxazepam; Rats

Indexed keywords

ANXIOLYTIC AGENT; BUSPIRONE; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; OXAZEPAM; SEROTONIN UPTAKE INHIBITOR;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ELECTRIC SHOCK; FIGHTING; MALE; NONHUMAN; RAT; STRESS; AGGRESSION; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; WISTAR RAT;

AGGRESSION; ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; ELECTROSHOCK; MALE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; STRESS;

EID: 0036384927     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Anisman H., Zacharko R.M.: Pharmacological biochemical and behavioral analyses of depression: animal models. In: Animal Models of Depression. Eds. Koob G.F., Ehlers C.L., Kupfer D.J., Birkhäuser, Boston 1989, 204-238.
2. 2 binding sites in the frontal cortex of suicide victims and control subjects. Amer. J. Psychiat., 1989, 146, 730-736.
3. 3H-LSD) in the blood platelets of depressed patients. Life Sci., 1989, 44, 725-734.
4. Barrett J.E., Vanover K.E.: 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmocology, 1993, 112, 1-12.
5. Barrett J.E., Witkin J.M., Mansbach R.S., Skolnick P., Weissman B.A.: Behavioural studies with anxiolytic drugs. III. Antipunishment actions of buspirone in pigeons do not involve benzodiazepine receptor mechanisms. J. Pharmacol. Exp. Ther., 1986, 238S, 1009-1013.
6. Beasley Ch.M., Masica D.N., Potvin J.H.: Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmocology, 1992, 107, 1-10.
7. Bel N., Artigas F.: Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse, 1993, 15, 243-245.
8. Blanchard R.J., Blanchard D.C.: Aggressive behaviour in the rat. Behav. Biol., 1977, 21, 197-224.
9. De Paulis T., Kumar Y., Johansson L., Ramsby L., Hall H., Sallemark M., Angeby-Moller K., Ögren S.-O.: Potential neuroleptic agents 4: chemistry, behavioral pharmacology, and inhibition of (3H)-spiperone binding of 3,5 disubstituted-((1-ethyl-2pyrroliolinyl)-methyl)-6-methoxy-salicylates. J. Med. Chem., 1986, 29, 61-69.
10. 1A receptor antagonists. Psychopharmacology, 1995, 119, 47-54.
11. 1A receptors in anxiety. In: New Concepts in Anxiety. Eds. Briley M., File S.E., MacMillan Press, London, 1991, 94-129.
12. 1A Receptors in Depression and Anxiety. Eds. Stahl S.M., Gastpar M., Keppel Hasselink J.M., Traber J., Raven Press, New York, 1992, 55-81.
13. Eison A.S., Temple D.L. Jr.: Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Amer. J. Med., 1986, 80, 1-9.
14. Fabre L.F.: Buspirone in the management of major depression: a placebo-controlled comparison. J. Clin. Psychiat., 1990, 51, 55-61.
15. Fontenay W., Le Cornec J., Zaczyńska M., Debarle M.C., Simon P., Boissier J.-R.: Problèmes posés par l'utilisation de trois tests de comportement du rat pour l'étude des médicaments psychotropes. J. Pharmacol. (Paris), 1970, 1, 243-254.
16. 1A agonists. Biol. Psychiat., 1988, 23, 237-242.
17. Gleeson S., Ahlers S.T., Mansbach R.S., Foust J.M., Barrett J.E.: Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J. Pharmacol. Exp. Ther., 1989, 250, 809-817.
18. Goa K.L., Ward A.: Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs, 1986, 32, 114-129.
19. Griffiths J., Shanks N., Anisman H.: Strain-specific alterations in comsumption of a palatable diet following repeated stressor exposure. Pharmacol. Biochem. Behav., 1992, 42, 219-227.
20. Handley S.L., Mc Blane J.W.: 5-HT drugs in animal models of anxiety. Psychopharmacology, 1993, 112, 13-20.
21. Katz R.J.: Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol. Biochem. Behav., 1982, 16, 965-968.
22. Katz R.J., Roth K.A., Caroll B.J.: Acute and chronic stress effects on open field activity in the rat: implication for a model of depression. Neurosci. Biobehav. Rev., 1981, 5, 247-251.
23. Katz R.J., Sibel M.: Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds. Pharmacol. Biochem. Behav., 1982, 16, 973-977.
24. Kendler K.S., Kessler R.C., Walters E.E., MacLean C., Neale M.C., Health A.C., Eaves L.J.: Stressful life events, genetic liability, and onset of major depression in women. Amer. J. Psychiat., 1995, 152, 833-842.
25. McKeith I.G., Marshall E.F., Ferrier I.N., Armstrong M.M., Kennedy W.N., Perry R.H., Perry E.K., Eccleston D.: 5-HT receptor binding in post-mortem brain from patients with affective disorder. J. Affect. Disorders, 1987, 13, 67-74.
26. McMillen B.A., Matthews R.T., Sanghera M.K., Shepard P.D., German D.C.: Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J. Neurosci., 1983, 3, 733-738.
27. Muscat R., Papp M., Willner R: Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology, 1992, 433-438.
28. 2 receptor-mediated behavior 11 days after shock in learned helplessness rats. Eur. J. Pharmacol., 1995, 281, 123-130.
29. Ossowska G., Klenk-Majewska B., Łupina T: The effect of calcium channel antagonists on the aggressive behavior in chronically stressed rats. Pol. J. Pharmacol., 1994, 46, 403-408.
30. Pandey G.N., Pandey S.C., Janicak P.G., Marks R.C., Davis J.M.: Platelet serotonin-2 receptor binding sites in depression and suicide. Biol. Psychiat., 1990, 28, 215-222.
31. Pich E.M., Samanin R.: Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology, 1986, 89, 125-130.
32. Rickels K., Amsterdam J.D., Clary C., Puzzuoli G., Schweizer E.: Buspirone in major depression: a controlled study. J. Clin. Psychiat., 1991, 52, 34-38.
33. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J. Clin. Psychopharmacol., 1990, 10, 67S-76S.
34. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Eds. Rodgers R.J., Cooper S.J., Wiley, Chichester, 1991, 365-376.
35. Sherman A.D., Sacquitne J.L., Petty F.: Specificity of the learned helplessness model of depression. Pharmacol. Biochem Behav., 1982, 16, 449-454.
36. Study R.E., Baker L.B.: Diazepam and (-)pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of γ-aminobutyric acid responses in cultured central neurons. Proc. Nat. Acad. Sci. USA, 1981, 78, 7180-7184.
37. 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology, 1995, 119, 15-19.
38. Taylor D.P., Moon S.L.: Buspirone and related compounds as alternative anxiolytics. Neuropeptides, 1991, 1, Suppl., 15-19.
39. Tedeschi D.H., Fowler P.J., Miller R.B., Macko E.: Pharmacological analysis of footshock-induced fighting behavior. In: Aggressive Behaviour. Eds. Garrattini S.S., Sigg K., Excerpta Medica, Amsterdam, 1969, 245-252.
40. Weissman B.A.: Interaction of buspirone with receptor binding sites. In: Buspirone: Mechanisms and Clinical Aspects. Eds. Tunnicliff G., Eison A.S., Taylor D.P., Academic Press, San Diego, 1991, 119-137.
41. Weissman B.A., Barrett J.E., Brady L.S., Witkin J.M., Mendelson W.B., Paul S.M., Skolnick P.: Behavioral and neurochemical studies on the anticonflict actions of buspirone. Drug Develop. Res., 1984, 4, 83-93.
42. 1A agonists measured with the forced swim test. Psychopharmacology, 1990, 101, 497-504.
43. Willner P.: Animal models as simulations of depression. Trends Neurosci., 1991, 121, 131-136.
44. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R.: Reduction of sucrose preference by chronic unpredictable mild stress and its restoration by a tricyclic antidepressant. Psychopharmacology, 1987, 93, 358-364.
45. Zebrowska-Łupina I., Ossowska G., Klenk-Majewska B.: Chronic stress reduced fighting behavior of rats: the effect of antidepressants. Pharmacol. Biochem. Behav., 1991, 39, 293-296.
46. Zebrowska-Łupina I., Ossowska G., Klenk-Majewska B.: The influence of antidepressants on aggressive behavior in chronically stressed rats: the role of dopamine. Pol. J. Pharmacol. Pharm., 1992, 44, 325-335.